Liposome Market

Liposome Market Outlook (2024 to 2034)

The global liposome market is estimated to be valued at US$ 8,670.7 million in 2024 and is forecast to reach a value of US$ 17,123.1 million by 2034, with a projected CAGR of 7% from 2024 to 2034.

The importance of liposome formulations in the global pharmaceutical sector is increasing day by day due to ongoing developments in drug delivery technologies. This is expected to stimulate market growth.

Pharmaceutical companies are the primary consumers of liposomes, as they utilize liposome encapsulations to deliver medicinal chemicals in a focused and regulated manner.

Liposome Market Trends and Analysis

The rising emphasis on research and development in the field of nanomedicine is driving the use of liposome technology in drug delivery advancements. Prominent manufacturers of liposomes are increasingly adapting their production techniques to meet the needs of pharmaceutical businesses looking for liposomal nanoparticles as efficient delivery methods.

The demand for sophisticated medication delivery solutions is rising with the advancement of the biopharmaceutical sector to suit the changing requirements of pharmaceutical firms with the advent of specialized treatments. So, established market participants are focusing more on the development of nanoliposomes that can be utilized for delivering a range of bioactive substances, such as proteins and nucleic acids. This is stimulating the market’s progress.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 8,670.7 million
Forecasted Market Value (2034F)	US$ 17,123.1 million
Global Market Growth Rate (2024 to 2034)	7% CAGR
Formulated Liposomes Segment Growth Rate (2024 to 2034)	7.1% CAGR
Drug Delivery Segment Growth Rate (2024 to 2034)	7.1% CAGR
Distributional Sales Segment Growth Rate (2024 to 2034)	7.1% CAGR
North America Market Share (2024)	7%
East Asia Market Share (2024)	8.6%
Key Companies Profiled	Novartis AG (Liposoma BV) Precision NanoSystems Inc Janssen Pharmaceutical Companies (Johnson & Johnson Encapsula Nano Sciences Synpac-Kingdom Pharmaceutical Co., Ltd Celsion GmbH Gilead Sciences, Inc Pacira BioSciences, Inc. Luye Pharma Group Sun Pharma Industries Ltd Shanghai New Asia Pharmaceutical Co., Ltd. ENERGY DELIVERY SOLUTIONS Creative Biolabs Nanovex Biotechnologies SL Insys Therapeutics Inc. Fujifilm Holdings Corporation Virpax Pharmaceuticals Azaya Therapeutics Avanti Polar Lipids, Inc. Breath Therapeutics (Zambon company) Getwell Taiwan Liposome Company Ltd Fresenius Health Care Group Xellia Pharmaceuticals (Novo Holdings A/S) Jazz Pharmaceuticals plc Ipsen Biopharmaceuticals, Inc. Baxter GMPriority Pharma S.G. Biopharm Pvt. Ltd

What is Fueling Growth in the Liposome Market?

“Expanding Biopharmaceutical Pipelines and Prevalence of Chronic Diseases”

Soaring adoption of customized medication delivery methods has become vital in recent years as drug therapy is gradually advancing toward individualized care. So, pharmaceutical companies or drug manufacturing firms are witnessing a greater requirement for configurable drug delivery solutions through liposomes.

The need for efficient and focused medication delivery systems is also surging due to the growing burden of chronic illnesses, particularly among the elderly. Moreover, pharmaceutical businesses that deal with chronic illnesses have directed their efforts toward liposome research to develop powerful liposomal encapsulations that can carry medications to predetermined targets.

Country-wise Insights

Country	Regional Market CAGR (2024 to 2034)
United States	7.1% CAGR
China	9.7% CAGR

What is Propelling the Demand for Liposomes in the United States?

“Nexus of Pharmaceutical Companies and Liposome Manufacturers in the United States”

The combined sales of liposome drug carriers in the United States, Canada, and Mexico are estimated to garner a revenue of around US$ 3,318 million in 2024, which is 38.3% of the global market. To fulfill the quality and performance requirements of highly developed pharmaceutical firms, market players in North America have become the flag bearers of technical breakthroughs in liposomal drug delivery research. The North American liposome industry is projected to advance at a CAGR of 7% over the forecasted period.

The United States is the leading market, holding 88.1% of the North America market share in 2024. Collaborative efforts in the United States have encouraged further innovation, resulting in the creation of new liposomal formulations and increasing the liposome applications for drug delivery. Over the next ten years, the liposome market is projected to expand further with a CAGR of 7.1% and retain its dominance in liposomal drug release.

Which Country is Ruling the Liposome Market in East Asia?

“Governmental Programs for Novel Drug Development in China and Japan”

In many Asian countries, government programs for medication development following the COVID-19 pandemic have stimulated pharmaceutical firms to explore cutting-edge delivery methods. East Asian market players support liposomal formulations that improve the medicinal agents' bioavailability and effectiveness. Consequently, the regional market is expected to witness a year-on-year growth rate of 8.6% and reach a valuation of US$ 2,931 million by 2034.

China is encouraging more production and use of liposomes for drug administration because of their great biological compatibility and good safety profile. During the projected years, the regional demand for liposomes is expected to surge at a 9.7% CAGR.

Category-wise Insights

Which Product Type is Widely Used by Liposome Manufacturing Industries?

“Dominance of Formulated Liposome for Targeted Cancer Therapies”

Attribute	Details
Market Share in 2024	69.5%

Among the different types of liposomes developed and utilized by pharmaceutical companies, the formulated liposomes segment is expected to remain dominant, with 69.5% of the total demand in 2024. Since formulated liposomes are well-known for their capacity to transport medications to cancer cells alone, their demand has increased with the advancement of targeted cancer therapy. Through the projection years, this segment is poised to progress with an annual growth rate of 7.1% and reach a valuation of US$ 11,962.1 million by the end of 2034.

The simple liposomes segment is anticipated to witness a CAGR of 6.3% over the next ten years. New market players are expected to take advantage of this trend by creating simple liposome formulations that require comparatively less capitalization. By experiencing this robust growth rate, this segment is expected to create a business opportunity of US$ 1,279.8 million by 2034, increasing from US$ 696.1 million in 2024.

Which Application Segment Drives Higher Demand for Liposome Formulation Techniques?

“Drug Delivery Remains the Primary Application of Liposomes”

Based on several applications of liposomal drug carriers, the drug delivery segment dominates, with an estimated market share of 91.2% in 2024. The creation of more stable and effective liposomal products, facilitated by ongoing technological advancements, is expected to further strengthen the application segment. Through the projected years, the segment is forecast to increase at a CAGR of 7.1% and reach a net worth of US$ 15,711.3 million by 2034.

The application of liposomes as contrast agents for medical imaging is also generating opportunities for present-day market players. Over the next ten years, the segment is poised to advance at a CAGR of 6.8% and reach US$ 375.9 million by 2034.

Competitive Landscape

Key players in the liposome industry include Novartis AG (Liposoma BV), Precision NanoSystems Inc., Janssen Pharmaceutical Companies (Johnson & Johnson), Encapsula Nano Sciences, Synpac-Kingdom Pharmaceutical Co., Ltd, Celsion GmbH, Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Sun Pharma Industries Ltd, Shanghai New Asia Pharmaceutical Co., Ltd., ENERGY DELIVERY SOLUTIONS, Creative Biolabs, Nanovex Biotechnologies SL, Insys Therapeutics Inc., Fujifilm Holdings Corporation, Virpax Pharmaceuticals, Azaya Therapeutics, Avanti Polar Lipids, Inc., Breath Therapeutics (Zambon company), Getwell, Taiwan Liposome Company Ltd, Fresenius Health Care Group, Xellia Pharmaceuticals (Novo Holdings A/S), Jazz Pharmaceuticals plc, Ipsen Biopharmaceuticals, Inc., Baxter, GMPriority Pharma, and S. G. Biopharm Pvt. Ltd.

The liposome market is considered consolidated, as only a few industry participants cater to more than 50% of the global market demand. A significant rise in research and development partnerships between pharmaceutical corporations and liposome producers in the last few years has further strengthened the market position of leading players.

Recent Developments

• In June 2022, Endo International PLC entered into a partnership with Taiwan Liposome Company through its subsidiary Endo Ventures Limited (EVL). Both firms agreed to a commercialization agreement for the development of a TLC's medication TLC599, which is under investigation. It is now in phase 3 research and TLC claims it is helpful to relieve knee discomfort associated with osteoarthritis. Taiwan Liposome Company, popularly known as TLC, is a clinical-stage specialty pharmaceutical firm in the country.

• In January 2022, a liposome-encapsulated version of the tubulin inhibitor taxane chemical paclitaxel was developed by Sun Pharma Advanced Research Company. The pharmaceutical company claims it to be a highly advanced medication that can be used for the treatment of breast cancer.

Key Segments Covered by Liposomes Industry Survey Report

• By Product Type :

  • Simple Liposomes
  • Formulated Liposomes
    • Doxorubicin Liposomes
    • Amphotericin B Liposomes
    • Paclitaxel Liposomes
    • Cytarabine Liposomes
    • Irinotecan Liposomes
    • Cisplatin Liposomes
    • Other Formulated Liposomes
  • Vaccines

• By Application :

  • Drug delivery
    • Cancer
    • Fungal Infection
    • Viral & Parasite Infection
    • Other Drug Deliveries
  • Gene Delivery or Transfection
  • Contrast agents for medical imaging
  • Model Cell Membranes
  • Other Applications

• By Distribution Channel :

  • Retail Sales
    • Academic & Research Laboratories
    • Biopharmaceutical Companies
    • Clinical Research Organizations
    • Other Retail Sales
  • Distributional Sales
    • Hospital Pharmacies
    • Retail Pharmacies
    • Mail Order Pharmacies
    • Drug Stores
    • Other Distribution Sales

• By Region :

  • North America Market
  • Europe Market
  • Latin America Market
  • East Asia Market
  • South Asia & Oceania Market
  • Middle East & Africa (MEA) Market